Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Hepatitis C 1

Interventions

Cyclophosphamide 139Rituximab 115Etoposide 77Vincristine 75Doxorubicin 62Cytarabine 61Dexamethasone 58Prednisone 55fludarabine 52Methotrexate 46N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 42Lenalidomide 37Gemcitabine 35Radiotherapy 29Melphalan 27pegaspargase 22Prednisolone 22Ifosfamide 22fludarabine phosphate 20Busulfan 20Cisplatin 19Bendamustine Hydrochloride 19Asparaginase 18Peripheral Blood Stem Cell Transplantation 17ibrutinib 16Decitabine 16Carmustine 16Mercaptopurine 15Filgrastim 15Oxaliplatin 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × ledipasvir, sofosbuvir drug combination × Lymphoid × Clear all
NCT03261349 2017-08-25

Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma

National Taiwan University Hospital

Phase 2 Unknown
21 enrolled
Lymphoid

Hepatitis C, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡